Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 708M 620M 572M 534M 1B 67B 1.02B 6.86B 2.66B 33.01B 2.66B 2.6B 115B P/E 2026 *
3.57x
P/E 2027 * 3.41x
Enterprise Value 708M 620M 572M 534M 1B 67B 1.02B 6.86B 2.66B 33.01B 2.66B 2.6B 115B EV / Sales 2026 *
1.54x
EV / Sales 2027 * 1.48x
Free-Float
96.84%
Yield 2026 *
-
Yield 2027 * -
1 day-2.09%
1 week+10.21%
Current month+17.93%
1 month+17.93%
3 months+37.58%
6 months+31.15%
Current year+24.93%
1 week 3.79
Extreme 3.79
4.36
1 month 3.14
Extreme 3.145
4.36
Current year 2.95
Extreme 2.95
5.78
1 year 0.67
Extreme 0.6701
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 01/04/2024
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Director

63,481 0.0386%
06-16Free

Director

63,481 0.0386%
06-16Free

Chairman

85,052 0.0517%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%+10.21%+476.00%-60.47% 708M
-0.68%+11.27%+62.45%+13.18% 320B
+0.31%+10.41%+30.36%-1.84% 72.69B
+1.41%+13.45%+49.91%+125.76% 9.15B
+0.37%+2.29%+5.85%-3.52% 8.33B
-4.94%+1.29%-5.15%+5.61% 4.62B
+0.98%+11.14%+12.81%+37.05% 3.99B
-4.88%-4.36%-32.24%+28.19% 3.57B
-0.62%+4.56%+49.26%+55.50% 2.72B
-1.71%+9.98%+15.61%-22.67% 2.18B
Average -1.32%+6.70%+66.49%+17.68% 42.75B
Weighted average by Cap. -0.36%+11.81%+54.00%+12.94%

Financials

2026 *2027 *
Net sales 459M 402M 371M 347M 652M 43.49B 664M 4.45B 1.73B 21.43B 1.73B 1.69B 74.68B 478M 419M 387M 361M 679M 45.28B 692M 4.64B 1.8B 22.31B 1.8B 1.76B 77.75B
Net income 188M 165M 152M 142M 267M 17.82B 272M 1.82B 708M 8.78B 707M 691M 30.59B 210M 184M 170M 158M 298M 19.86B 303M 2.03B 790M 9.79B 788M 771M 34.11B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
30/06/26 $4.210 -2.09% 2,583,816
29/06/26 $4.300 +4.12% 3,501,858
26/06/26 $4.130 +7.55% 7,108,527
25/06/26 $3.840 -1.79% 1,659,700
24/06/26 $3.910 +1.30% 1,764,481
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.210USD
Average target price
6.100USD
Spread / Average Target
+44.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock